Press Releases

Opus Genetics Leadership to Present at BTIG Ophthalmology Day

Research Triangle Park, N.C. – Nov. 22, 2022 – Opus Genetics, a patient-first gene therapy company developing treatments for inherited retinal diseases, today announced that Ben Yerxa, Ph.D., Chief Executive Officer of Opus, will participate in a fireside chat during the virtual BTIG Ophthalmology Day on Tuesday, November 29, 2022, at 2:30 p.m. ET.

BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative with interest. For more information on Opus’ upcoming events and presentations, click here.

About Opus Genetics

Opus Genetics is a groundbreaking gene therapy company for inherited retinal diseases with a unique model and purpose. Backed by Foundation Fighting Blindness’s venture arm, the RD Fund, Opus combines unparalleled insight and commitment to patient need with wholly owned programs in numerous orphan retinal diseases. Its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. Based in Research Triangle Park, N.C., the company leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. For more information, visit


Opus Media Contact:
Heather Anderson
6 Degrees